Annexon, Inc. (ANNX)
NASDAQ • Healthcare
Last close at October 22, 2026 at 20:00 UTC
Metrics Over Time
Fundamentals & Financials
TTM is calculated as the sum of the four most recently completed quarters. This is a standard approach when monthly or real-time data is not available.
Income Statement
Balance Sheet
Financial Highlights
Dividends History
Split History
Earnings
Nov 9
in 17 daysQ4 2026% — EPS deviation from the forecast (beat / miss); quarters without a forecast show the reported EPS
Annexon’s EPS of -$0.28 trailed the -$0.24 estimate, -17%, as it reported preliminary second fiscal quarter of 2026 results on Aug. 12. Operating loss came to about $57.2 million, net income was a loss of about $55.3 million, down 12.6% from a loss of about $49.2 million a year ago, and operating cash flow was negative about $48.0 million. Consensus for the next period calls for EPS of -$0.26 on revenue of $3.5 million.
Next report — what to expect
Annexon, Inc. (ANNX) reports next on November 9, 2026. Wall Street is looking for EPS of -$0.28 on revenue of $3.5 million. Recent results have been mixed, with the company beating EPS in 4 of 8 most recent quarters, so traders may focus on any deviations from these consensus benchmarks.
About Annexon, Inc.
Annexon, Inc. is a NASDAQ-listed biotechnology company developing therapies that act on the classical complement pathway through the C1q molecule. The company focuses on autoimmune, neurodegenerative, and ophthalmic conditions, and operates as a clinical-stage business from Brisbane, California after its 2020 public listing.
Today's Snapshot
ANNX is trading 2.9% below yesterday's close, in line with a weaker sector.
Trading Volume
Below 10d avg (3.9M)
881.2K
vs S&P 500 Today
Underperforming Market
-2.69%
Updated: October 23, 2026 at 16:55 UTC
Technical Indicators
All signalsHide signals
- EMA (5 indicators)$3.81 - $4.83Sell
- RSI (14)41.51Neutral
- Stochastic %K (14, 3, 3)46.11Neutral
- MACD Level (12, 26)-0.16Neutral
Peers & Related Assets
Get premium market insights delivered directly to your inbox.